MedTrace Logo

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

NCT06761976 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option.

Conditions

Interventions

DRUG

Sevabertinib

Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06761976 on ClinicalTrials.gov